Clifford Salinger, MD
Ophthalmology · Palm Beach Gardens, FLNPI 1891888418
Payments from drug & device makers
Across 387 payments — averaging $420.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$57K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$35K
- Sun Pharmaceutical Industries Inc.$23K
- Shire North American Group Inc$16K
- Biotissue Holdings Inc.$13K
- Kala Pharmaceuticals, Inc.$7K
- plus $10K from 20 others
Across 1 payment — averaging $21,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch & Lomb Americas Inc.$22K
What the payments were for
- Consulting fees$19,57512%
- Speaking & faculty fees$115,70671%
- Travel & lodging$16,42310%
- Food & beverage$10,8167%
- Education$2940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 71 | $57,334 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 58 | $35,071 |
| Sun Pharmaceutical Industries Inc. | 37 | $23,457 |
| Shire North American Group Inc | 22 | $16,119 |
| Biotissue Holdings Inc. | 23 | $13,314 |
| Kala Pharmaceuticals, Inc. | 20 | $7,026 |
| Oyster Point Pharma, Inc. | 6 | $2,936 |
| Tarsus Pharmaceuticals, Inc. | 12 | $1,905 |
| Eyevance Pharmaceuticals LLC | 14 | $1,772 |
| Mallinckrodt Hospital Products Inc. | 26 | $827 |
| ANI Pharmaceuticals, Inc. | 15 | $472 |
| Novartis | 18 | $448 |
| Bausch & Lomb Americas Inc. | 19 | $356 |
| Sight Sciences, Inc. | 6 | $333 |
| AbbVie(2 entities) | 6 | $227 |
| Alcon | 10 | $224 |
| Ocular Therapeutix, Inc. | 3 | $216 |
| Omeros Corporation | 3 | $212 |
| Amgen(2 entities) | 6 | $160 |
| Genentech USA, Inc. | 1 | $99 |
| Harrow Eye, LLC | 3 | $86 |
| Mallinckrodt Enterprises LLC | 3 | $68 |
| Optovue, Inc. | 1 | $62 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $47 |
| Eyepoint US, Inc. | 1 | $22 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$56,355
- LOTEMAX SM$33,793
- CEQUA$22,944
- XIIDRA$15,888
- Prokera$12,496
- AmnioGraft$12,496
- AmnioGuard$12,132
- EYSUVIS$6,740
- TYRVAYA$2,750
- Flarex$1,414
- ACTHAR$150
- TearCare SmartLid$130
- TEARCARE(TM) (2.2) SYSTEM KIT$130
- OMIDRIA$125
- TearCare$122
- PURIFIED CORTROPHIN GEL$121
- BROMSITE$116
- XELPROS$116
- Tobradex ST$109
- DEXTENZA$100
How this compares
$162,814 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 34 | $959,546 |
| RestasisCyclosporine | 147 | $130,993 |
| Loteprednol Etabonate | 543 | $68,676 |
| XiidraLifitegrast | 24 | $34,906 |
| CequaCyclosporine | 15 | $17,554 |
| LumiganBimatoprost | 24 | $14,006 |
| MieboPerfluorohexyloctane/Pf | 18 | $13,460 |
| RhopressaNetarsudil Mesylate | 24 | $13,347 |
| Lotemax SmLoteprednol Etabonate | 51 | $12,905 |
| VyzultaLatanoprostene Bunod | 23 | $12,351 |
| TyrvayaVarenicline Tartrate | 16 | $11,308 |
| ZirganGanciclovir | 20 | $9,431 |
| Fluorometholone | 104 | $8,811 |
| Cyclosporine | 20 | $8,354 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 36 | $7,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $57,334 | $959,54634 claims |
| AbbVieRestasis, Lumigan, Combigan | $227 | $151,367190 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Prolensa, Lotemax | $35,071 | $91,216624 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta, Zirgan | $356 | $70,14885 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $23,457 | $17,55415 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $19 | $13,34724 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $2,936 | $11,30816 claims |
| AlconSimbrinza | $224 | $7,36436 claims |
| Eyevance Pharmaceuticals LLCFlarex | $1,772 | $3,08224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Palm Beach Gardens
- Mark MilnerPalm Beach Gardens$1.2M
- Jorge FortunPalm Beach Gardens$940K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.